Chongqing Lummy Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products in China. It provides anti-tu...
Lummy Pharmaceuticals has continuously received a Wind ESG BBB rating, with a comprehensive score of 6.77
Lummy: Product Nicorandil tablets intend to be selected for the 11th batch of national drug procurement
Lummy Pharmaceuticals released its performance for the first three quarters, with a net loss attributable to the parent company of 45.9172 million yuan
The pharmaceutical sector fluctuates and strengthens, ASK PHARM hits the limit up
Lummy obtained two drug registration certificates
Lummy: The equity structure of the indirect controlling shareholder is expected to change